For research and educational purposes only. Not medical advice.
Survodutide Reference
Educational, not medical advice reference for Survodutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also know…
Reference summary
Phase 2 data have been published and Phase 3 trials are underway. pepSmart displays survodutide only as trial-context educational content.
- Categories
- GLP-1, Fat Loss
- Aliases
- BI 456906, GLP-1/glucagon dual agonist
- Evidence posture
- human — Human trial data exist, but survodutide remains investigational.
- Regulatory status
- Investigational. Survodutide is a GLP-1/glucagon dual receptor agonist in Boehringer Ingelheim and Zealand Pharma Phase 3 obesity trials (SYNCHRONIZE program). There is no FDA-approved drug label, and survodutide is not on FDA's approved bulk-substances list for compounding.
- Content review status
- investigational verified